psalexa
P&S Market Research - A market research firm

Premature Ejaculation Therapeutics Pipeline Analysis

Premature Ejaculation Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Delivery : 1-2 Working Days
Report Code: LS11272
Available Format:

Premature ejaculation is a type of male sexual disorder with an intravaginal ejaculatory latency time of less than one minute. High levels of sexual anxiety and altered sensitivity of serotonin receptors are found as an evidence in most of the men with premature ejaculation. Premature ejaculation can be defined by three criteria such as lack of sexual satisfaction, short ejaculatory latency, and lack of control over ejaculation. Some of the risk factors associated with premature ejaculation are endocrinopathy, opiate withdrawal, chronic prostatitis, and alcohol abuse. CTC Bio, Inc. is in the process of developing CDFR0812 as an adrenergic uptake inhibitor for the treatment of premature ejaculation. Ixchelsis Limited is in the process of developing IX-01 as an oxytocin receptor antagonist for the treatment of premature ejaculation. Some of the companies and universities having the pipeline of premature ejaculation include CTC Bio, Inc., Allergan plc, Ixchelsis Limited, and others.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 3250
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 4000
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry